BURLINGAME, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc., a biopharmaceutical company pioneering the use of embryonic stem cells as proprietary biological systems for discovery and development of novel drugs for the treatment of diabetes and central nervous system disorders, announced today the renewal of its strategic partnership with Sanwa Kagaku Kenkyusho Co. Ltd. (“Sanwa”), an international pharmaceutical company headquartered in Nagoya, Japan. Continuing the successful initial phase of the collaboration, VistaGen will apply its core embryonic stem cell technologies to discover critical biological molecules, growth factors, and drug targets related to ß-islet cell growth and insulin production. Sanwa will use VistaGen’s customized, proprietary stem cell-based assays to screen its compound libraries for new drug candidates for treatment of both Type 1 and Type 2 diabetes. This strategic partnership represents the first collaborative pharmaceutical application of embryonic stem cells to discover novel therapeutics for the treatment of diabetes.
